# Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

> **NCT03832517** · PHASE1 · TERMINATED · sponsor: **Recida Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Safety

## Interventions

- **DRUG:** Single intravenous doses of RC-01
- **DRUG:** Single intravenous doses of placebo
- **DRUG:** Multiple intravenous doses of RC-01
- **DRUG:** Multiple intravenous doses of placebo

## Key facts

- **NCT ID:** NCT03832517
- **Lead sponsor:** Recida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-14
- **Primary completion:** 2019-04-22
- **Final completion:** 2019-05-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** safety
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832517, "Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03832517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*